[HTML][HTML] Trial of prasinezumab in early-stage Parkinson's disease
Background Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues
V Lakics, EH Karran, FG Boess - Neuropharmacology, 2010 - Elsevier
Cyclic nucleotide-specific phosphodiesterases (PDEs) play a critical role in signal
transduction by regulating the level of adenosine 3′,5′-cyclic monophosphate (cAMP) and …
transduction by regulating the level of adenosine 3′,5′-cyclic monophosphate (cAMP) and …
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance
FG Boess, M Hendrix, FJ van der Staay, C Erb… - …, 2004 - Elsevier
An essential element of the signalling cascade leading to synaptic plasticity is the intracellular
second messenger molecule guanosine 3′,5′-cyclic monophosphate (cGMP). Using …
second messenger molecule guanosine 3′,5′-cyclic monophosphate (cGMP). Using …
Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti–α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized …
…, M Grundman, J Soto, S Ostrowitzki, FG Boess… - JAMA …, 2018 - jamanetwork.com
Importance Aggregated α-synuclein is believed to be central to the pathogenesis of Parkinson
disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed …
disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed …
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 …
…, R Chesworth, G Shapiro, FG Boess… - …, 2012 - Elsevier
EVP-6124, (R)-7-chloro-N-quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, is a novel
partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs) that was evaluated …
partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs) that was evaluated …
The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo [2.2. 2] oct-3-yl]-7-[2-(methoxy) phenyl]-1-benzofuran-2-carboxamide improves working and …
FG Boess, J De Vry, C Erb, T Flessner, M Hendrix… - … of Pharmacology and …, 2007 - ASPET
The relative contribution of α4β2, α7 and other nicotinic acetylcholine receptor (nAChR)
subtypes to the memory enhancing versus the addictive effects of nicotine is the subject of …
subtypes to the memory enhancing versus the addictive effects of nicotine is the subject of …
Ultrastructure of the 5‐Hydroxytryptamine3 Receptor
FG Boess, R Beroukhim, IL Martin - Journal of neurochemistry, 1995 - Wiley Online Library
We have determined the ultrastructure of 5‐hydroxytryptamine 3 (5‐HT 3 ) serotonin receptors
purified from NG108‐15 mouse neuroblastoma × rat glioma cells by electron microscopic …
purified from NG108‐15 mouse neuroblastoma × rat glioma cells by electron microscopic …
Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors
AJ Sleight, FG Boess, M Bös… - British journal of …, 1998 - Wiley Online Library
This study describes the in vitro characterization of two potent and selective 5‐HT 6 receptor
antagonists at the rat and human recombinant 5‐HT 6 receptor. In binding assays with [ 3 H]…
antagonists at the rat and human recombinant 5‐HT 6 receptor. In binding assays with [ 3 H]…
[HTML][HTML] A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical
progression nor target alpha-synuclein, a key protein associated with the disease. Objective…
progression nor target alpha-synuclein, a key protein associated with the disease. Objective…
Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats
JC Bentley, A Bourson, FG Boess… - British journal of …, 1999 - Wiley Online Library
The present study examined the effects of the selective 5‐HT 6 receptor antagonist 4‐amino‐N‐(2,
6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on …
6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on …